1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
TransEnterix, Inc.

TransEnterix, Inc.

TRXDW
TransEnterix, Inc.US flagOther OTC
0.15
USD
-0.02
- -
40.09MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
2
1
- -
- -
2
7
24
9
3
8
7
9
10
Operating Margin (%)
- -
-712.72
-1,554.37
-9,129.43
- -
-3,670.44
-833.55
-266.99
-1,075.38
-1,783.12
-803.98
-1,063.4
-910.92
-723.08
Depreciation Expense
- -
2
1
1
3
9
10
13
12
14
14
11
4
4
Net Income, GAAP
-6
-15
-28
-38
-47
-120
-145
-62
-154
-59
-62
-76
-78
-84
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-729.31
-1,981.69
-9,389.53
- -
-7,898.62
-2,036.23
-256.31
-1,807.54
-1,868.09
-758.77
-1,066.19
-914.46
-850.75
Working Capital
- -
9
11
31
18
7
84
80
15
24
103
76
24
-20
LT Debt
3
8
5
9
13
5
8
29
- -
2
5
5
5
4
Total Equity
-2
-69
105
122
177
118
179
169
56
62
169
100
33
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
1
1
16
LT Borrowings
- -
- -
- -
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
272
273
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
36
19
19
Cash, Cash Equivalents & STI
21
8
8
Accounts Receivable, Net
4
1
- -
Inventories
7
6
7
Total Current Liabilities
13
19
40
Payables & Accruals
6
5
5
ST Debt
1
1
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.51%
2.22%
-66.47%
Free Cash Flow
14.88%
10.62%
6.6%
Net Income, GAAP
29.45%
23.63%
3.8%
Sales/Revenue/Turnover
- -
7.8%
21.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
3
2
7
2023
1
1
1
5
9
2024
1
2
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Anthony Fernando
Full Time Employees
207
Sector
Healthcare
Industry
Medical - Specialties
Address
United States of America
Similar Companies
LifeTech Scientific Corporation (1302.HK)
Alpha Tau Medical Ltd. (DRTSW)
The Klinique Medical Clinic Public Company Limited (KLINIQ.BK)
T&R Biofab Co., Ltd. (246710.KQ)
Micro-X Limited (MX1.AX)
Genex Pharmaceutical, Inc. (GENX)
Business
TransEnterix, Inc. (TRXDW) is a medical device company that develops and commercializes robotic-assisted surgical systems to advance minimally invasive surgery; its flagship Senhance Surgical Robotic System integrates 3D high-definition visualization, haptic feedback, eye-tracking camera control, and Intelligent Surgical Unit for augmented intelligence, supporting laparoscopic procedures in urology, gynecology, general surgery, and other specialties with 3mm instruments, articulating tools, hooks, and ultrasonic energy devices for tissue ligation; the company also pursues next-generation platforms like LUNA for enhanced precision and machine learning-driven insights. Founded in 1995 and headquartered in Durham, North Carolina, TransEnterix, Inc. (TRXDW) operates primarily in North America, Europe, the Middle East, Africa, and Asia, with regulatory clearances including FDA approvals in the United States and CE Mark in Europe. In May 2021, the company rebranded to Asensus Surgical, Inc. to emphasize digital laparoscopy; more recently, in August 2024, KARL STORZ SE & Co. KG completed its acquisition of the company for $0.35 per share in cash, totaling approximately $95 million, integrating Senhance and LUNA development into KARL STORZ's endoscopy portfolio to create a surgical robotics hub while retaining over 200 team members for ongoing R&D and global commercialization.

Company News

APIChatGPT

  • defenseworld.net

    Reviewing TransEnterix (OTCMKTS:TRXDW) and Check-Cap (NASDAQ:MBAI)